Tag Archives: Sankalp Rehabilitation Trust

Indian Court Limits Frivolous Drug Patenting, Clearing Path to Affordable Medicines

Source: Open Society Foundations Azadeh Momenghalibaf /January 3, 2013 Should pharmaceutical patents—which result in monopolistic pricing of medicines—apply to any new drug, regardless of how it was made and whether it offers anything new? This question was answered recently in … Continue reading

Posted in Evergreening, Hepatitis C | Tagged , , , | Leave a comment

Roche concerned about ‘neglect’ of patent rules in India, but stays committed

Source: Scripintelligence Anju Ghangurde, 10-Nov-12 Days after a second patent-related setback in India in recent times, Roche says that it is concerned about a “policy of neglect” for patent rules that would inhibit future research, though the Swiss firm stressed that … Continue reading

Posted in Evergreening, Sec 3 (d), TRIPS | Tagged , , | 1 Comment

Breaking News: Patent on Pegylated Interferon alpha 2a revoked by IPAB Chennai

Intellectual Property Appellate Board (IPAB), Chennai (India) has set aside the patent granted to Roche for pegylated interferon alfa-2a (sold by Roche under the brand name Pegasys). The invention (interferon alpha-2a + polyethyleneglycol) was held to be obvious. A copy of … Continue reading

Posted in Evergreening, Patent Opposition | Tagged , | 2 Comments

Cancer drug patent revoked by Indian patent office

Cipla had submitted a post grant opposition to the patent IN209251 granted in 2007 to SUGEN INC., USA and Parmacia and Upjohn Co for Sunitinib (brand name: Sutent), a drug used in the treatment of Renal Cell Carcinoma (RCC). The … Continue reading

Posted in Indian Patent Law, Patent Opposition | Tagged , , , | Leave a comment